search
Back to results

Abiliti™ Treatment in Obese Subjects

Primary Purpose

Obesity, Morbid Obesity

Status
Unknown status
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
abiliti system implant
Laparoscopic adjustable gastric band (Allergan Lap Band)
Sponsored by
IntraPace, Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring obesity, gastric stimulation, morbid obesity

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age of 18 - 60 years old at time of screening
  • BMI of 40 to 55 or 35 to 39 with an obesity related comorbid condition at time of screening
  • History of obesity ≥5 years
  • The subject has been under routine care of the investigator or another single physician that can supply a medical record for at least 6 months prior to enrollment
  • Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods
  • No significant weight loss (<5%) within four months prior to enrollment as documented in the subject's medical record.
  • Successful psychological evaluation following the institution psychological evaluation protocol for bariatric surgery or successful historic assessment performed no more than 6 months prior to enrollment.
  • Glycosylated Hemoglobin; HbA1c ≤ 7.0 % at Visit 2 or historic value performed no more than 3 months prior to enrollment.
  • If taking anti-depressant medications, they must be stable for at least six months prior to enrollment
  • Willingness to refrain from using prescription, over the counter or herbal weight loss products for the duration of the trial
  • Alert, mentally competent, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial
  • Able to provide voluntary informed consent

Exclusion Criteria:

  • Any prior bariatric surgery
  • Other implanted electrical stimulation devices (e.g. pacemaker, defibrillator, neurostimulator)
  • Diagnosed with past or current psychiatric condition that may impair his/her ability to comply with the study procedures
  • Use of anti-psychotic medications
  • Diagnosed with a eating disorder such as bulimia or binge eating
  • Obesity due to an endocrinopathy (e.g. Cushing disease)
  • Insulin therapy
  • GI disease such as hiatal hernia (>5cm), gastroparesis, esophageal motility disorders or intractable constipation.
  • Cirrhosis, chronic pancreatitis
  • History of intestinal obstruction or adhesive peritonitis
  • Any history of peptic ulcer disease within 5 years prior to enrollment
  • Women who are pregnant, lactating or anticipate becoming pregnant within 24 months
  • Arthritis or other pathologies limiting physical activities that physician feels should exclude the patient from the study.
  • Chronic use of aspirin and/or non steroidal anti-inflammatory medications and unwillingness to discontinue use
  • Cardiac history that physician feels should exclude the patient from the study.
  • Concurrent use of weight loss medications.
  • Use of another investigational device or agent in the 30 days prior to enrollment
  • A history of life-threatening disease within 5 years prior to enrollment
  • Any other condition that, in the opinion of the investigator, would make the subject unsuitable for the study

Sites / Locations

  • Polyclinique de Rillieux, Clinique Lyon-NordRecruiting
  • MIC Ev. Krankenhaus HubertusRecruiting
  • SRH Wald-Klinikum GeraRecruiting
  • Wolfart Klinik
  • Universitätsklinikum Hamburg-EppendorfRecruiting
  • Stadtkrankenhaus SchwabachRecruiting
  • Azienda Ospedaliera- University
  • Clinica San Luca Torino
  • Vicenza Regional Hospital
  • Complutense University of Madrid Hospital Clinico "San Carlos"
  • Hospital Virgen del RocióRecruiting
  • Klinik LindbergRecruiting
  • Spire Southampton Hospital
  • St. Anthony's Hospital
  • Mid Yorkshire NHS Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

abiliti Group

Gastric Band Group

Arm Description

Subjects will receive implanted abiliti System. The device will be activated to deliver therapy at implant. Gastric stimulation performance testing, therapy adjustment and dietary/exercise counseling will be conducted at each visit.

Subjects will receive an implanted laparoscopic adjustable gastric band. The subjects will have their band adjusted following the standard of care. Dietary/exercise counseling will be conducted at each visit.

Outcomes

Primary Outcome Measures

Non-inferiority of the abiliti therapy compared to adjustable gastric banding
The non-inferiority of the abiliti therapy compared to adjustable gastric banding will be measured using a composite endpoint at the end of the study period. The success criteria will be the percentage of subjects in each group who meet all of the following criteria: Achieve at least 20% excess weight loss (%EWL) from implant to end of the study period. Experience no serious or severe adverse events related to the device or the procedure No significant negative change in quality of life using the Impact Of Weight On Quality Of Life-Lite Questionnaire (IWQOL-Lite)
Percentage of Responders
Fifty (50 %) of the subject population must obtain an EWL ≥ 25%
Safety
Incidence and seriousness of all adverse events. Incidence of device or procedure-related adverse events Frequency of clinically significant abnormal laboratory values as determined by the Investigator;

Secondary Outcome Measures

Safety
Frequency of device and procedure-related adverse events
Quality of Life
Change in the quality of life using the IWQOL-Lite questionnaire
Eating Behavior
Change in the eating behavior (cognitive restraint, uncontrolled eating, and emotional eating) using the Three Factor Eating Questionnaire (TFEQ).
Co-morbid Conditions
Evaluation of the changes in blood pressure, lipid panel, HbA1c

Full Information

First Posted
October 3, 2011
Last Updated
October 27, 2011
Sponsor
IntraPace, Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT01448785
Brief Title
Abiliti™ Treatment in Obese Subjects
Official Title
Abiliti™ Treatment in Obese Subjects: A Randomized Post-Market Surveillance Multicenter Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2011
Overall Recruitment Status
Unknown status
Study Start Date
April 2011 (undefined)
Primary Completion Date
January 2013 (Anticipated)
Study Completion Date
January 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
IntraPace, Inc

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The main objective of this post-market surveillance study is to compare the subject's weight loss and quality of life, and device safety performance of the abiliti System and the adjustable gastric banding therapies in obese to morbidly obese subjects.
Detailed Description
This study is intended to provide additional data regarding the performance and safety of the abiliti system in comparison to gastric banding. The composite end-point of the study is designed to provide a direct comparison of the effectiveness of the devices for the treatment of obesity while giving consideration to the safety profile for each device and their impact on patient quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Morbid Obesity
Keywords
obesity, gastric stimulation, morbid obesity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
165 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
abiliti Group
Arm Type
Active Comparator
Arm Description
Subjects will receive implanted abiliti System. The device will be activated to deliver therapy at implant. Gastric stimulation performance testing, therapy adjustment and dietary/exercise counseling will be conducted at each visit.
Arm Title
Gastric Band Group
Arm Type
Active Comparator
Arm Description
Subjects will receive an implanted laparoscopic adjustable gastric band. The subjects will have their band adjusted following the standard of care. Dietary/exercise counseling will be conducted at each visit.
Intervention Type
Device
Intervention Name(s)
abiliti system implant
Other Intervention Name(s)
abiliti
Intervention Description
Subjects will receive implanted abiliti System.
Intervention Type
Device
Intervention Name(s)
Laparoscopic adjustable gastric band (Allergan Lap Band)
Other Intervention Name(s)
gastric band
Intervention Description
Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
Primary Outcome Measure Information:
Title
Non-inferiority of the abiliti therapy compared to adjustable gastric banding
Description
The non-inferiority of the abiliti therapy compared to adjustable gastric banding will be measured using a composite endpoint at the end of the study period. The success criteria will be the percentage of subjects in each group who meet all of the following criteria: Achieve at least 20% excess weight loss (%EWL) from implant to end of the study period. Experience no serious or severe adverse events related to the device or the procedure No significant negative change in quality of life using the Impact Of Weight On Quality Of Life-Lite Questionnaire (IWQOL-Lite)
Time Frame
12 months
Title
Percentage of Responders
Description
Fifty (50 %) of the subject population must obtain an EWL ≥ 25%
Time Frame
12 months
Title
Safety
Description
Incidence and seriousness of all adverse events. Incidence of device or procedure-related adverse events Frequency of clinically significant abnormal laboratory values as determined by the Investigator;
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Safety
Description
Frequency of device and procedure-related adverse events
Time Frame
6 and 12 months
Title
Quality of Life
Description
Change in the quality of life using the IWQOL-Lite questionnaire
Time Frame
6 and 12 months
Title
Eating Behavior
Description
Change in the eating behavior (cognitive restraint, uncontrolled eating, and emotional eating) using the Three Factor Eating Questionnaire (TFEQ).
Time Frame
6 and 12 months
Title
Co-morbid Conditions
Description
Evaluation of the changes in blood pressure, lipid panel, HbA1c
Time Frame
6 and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age of 18 - 60 years old at time of screening BMI of 40 to 55 or 35 to 39 with an obesity related comorbid condition at time of screening History of obesity ≥5 years The subject has been under routine care of the investigator or another single physician that can supply a medical record for at least 6 months prior to enrollment Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods No significant weight loss (<5%) within four months prior to enrollment as documented in the subject's medical record. Successful psychological evaluation following the institution psychological evaluation protocol for bariatric surgery or successful historic assessment performed no more than 6 months prior to enrollment. Glycosylated Hemoglobin; HbA1c ≤ 7.0 % at Visit 2 or historic value performed no more than 3 months prior to enrollment. If taking anti-depressant medications, they must be stable for at least six months prior to enrollment Willingness to refrain from using prescription, over the counter or herbal weight loss products for the duration of the trial Alert, mentally competent, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial Able to provide voluntary informed consent Exclusion Criteria: Any prior bariatric surgery Other implanted electrical stimulation devices (e.g. pacemaker, defibrillator, neurostimulator) Diagnosed with past or current psychiatric condition that may impair his/her ability to comply with the study procedures Use of anti-psychotic medications Diagnosed with a eating disorder such as bulimia or binge eating Obesity due to an endocrinopathy (e.g. Cushing disease) Insulin therapy GI disease such as hiatal hernia (>5cm), gastroparesis, esophageal motility disorders or intractable constipation. Cirrhosis, chronic pancreatitis History of intestinal obstruction or adhesive peritonitis Any history of peptic ulcer disease within 5 years prior to enrollment Women who are pregnant, lactating or anticipate becoming pregnant within 24 months Arthritis or other pathologies limiting physical activities that physician feels should exclude the patient from the study. Chronic use of aspirin and/or non steroidal anti-inflammatory medications and unwillingness to discontinue use Cardiac history that physician feels should exclude the patient from the study. Concurrent use of weight loss medications. Use of another investigational device or agent in the 30 days prior to enrollment A history of life-threatening disease within 5 years prior to enrollment Any other condition that, in the opinion of the investigator, would make the subject unsuitable for the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Robert Nardelli
Phone
650-316-4065
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Horbach, MD
Organizational Affiliation
Stadtkrankenhaus Schwabach
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alberic Fiennes, MD
Organizational Affiliation
St Anthony's Hospital, Surrey, England
Official's Role
Principal Investigator
Facility Information:
Facility Name
Polyclinique de Rillieux, Clinique Lyon-Nord
City
RILLIEUX Cedex
ZIP/Postal Code
69165
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jerome Dargent, MD
First Name & Middle Initial & Last Name & Degree
Jerome Dargent, MD
Facility Name
MIC Ev. Krankenhaus Hubertus
City
Berlin
ZIP/Postal Code
14129
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Susewind, MD
First Name & Middle Initial & Last Name & Degree
Martin Susewind, MD
Facility Name
SRH Wald-Klinikum Gera
City
Gera
ZIP/Postal Code
07548
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christine Stroh, MD
First Name & Middle Initial & Last Name & Degree
Christine Stroh, MD
Facility Name
Wolfart Klinik
City
Graefelfing
ZIP/Postal Code
92166
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Universitätsklinikum Hamburg-Eppendorf
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Oliver Mann, MD
First Name & Middle Initial & Last Name & Degree
Oliver Mann, MD
Facility Name
Stadtkrankenhaus Schwabach
City
Schwabach
ZIP/Postal Code
91126
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Horbach, MD
First Name & Middle Initial & Last Name & Degree
Thomas Horbach, MD
Facility Name
Azienda Ospedaliera- University
City
Pisa
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marco Anselmino, MD
First Name & Middle Initial & Last Name & Degree
Marco Anselmino, MD
Facility Name
Clinica San Luca Torino
City
Turin
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giuseppe M Rovera, MD
First Name & Middle Initial & Last Name & Degree
Giuseppe M Rovera, MD
Facility Name
Vicenza Regional Hospital
City
Vicenza
ZIP/Postal Code
36100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Franco Favretti, MD
First Name & Middle Initial & Last Name & Degree
Franco Favretti, MD
Facility Name
Complutense University of Madrid Hospital Clinico "San Carlos"
City
Madrid
ZIP/Postal Code
28290
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonio J Torres, MD
First Name & Middle Initial & Last Name & Degree
Antonio J Torres, MD
Facility Name
Hospital Virgen del Roció
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Salvador Morales Conde, MD
First Name & Middle Initial & Last Name & Degree
Salvador Morales Conde, MD
Facility Name
Klinik Lindberg
City
Winterthur
ZIP/Postal Code
8400
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fritz Horber, MD
First Name & Middle Initial & Last Name & Degree
Fritz Horber, MD
Facility Name
Spire Southampton Hospital
City
Hampshire
State/Province
Southampton
ZIP/Postal Code
SO16 6UY
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
James Byrne, MD
First Name & Middle Initial & Last Name & Degree
James Byrne, MD
Facility Name
St. Anthony's Hospital
City
North Cheam
State/Province
Surrey
ZIP/Postal Code
SM3 9DW
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alberic Fiennes, MD
First Name & Middle Initial & Last Name & Degree
Alberic Fiennes, MD
Facility Name
Mid Yorkshire NHS Trust
City
Dewsbury
State/Province
West Yorkshire
ZIP/Postal Code
WF13 4HS
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chinnadorai Rajeswaran, MD
First Name & Middle Initial & Last Name & Degree
Chinnadorai Rajeswaran, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
29333595
Citation
Morales-Conde S, Alarcon Del Agua I, Busetto L, Favretti F, Anselmino M, Rovera GM, Socas-Macias M, Barranco-Moreno A, Province-Azalde R, Torres AJ. Implanted Closed-Loop Gastric Electrical Stimulation (CLGES) System with Sensor-Based Feedback Safely Limits Weight Regain at 24 Months. Obes Surg. 2018 Jun;28(6):1766-1774. doi: 10.1007/s11695-017-3093-8.
Results Reference
derived
PubMed Identifier
28164463
Citation
Busetto L, Torres AJ, Morales-Conde S, Alarcon Del Agua I, Moretto C, Fierabracci P, Rovera G, Segato G, Rubio MA, Favretti F. Impact of the feedback provided by a gastric electrical stimulation system on eating behavior and physical activity levels. Obesity (Silver Spring). 2017 Mar;25(3):514-521. doi: 10.1002/oby.21760. Epub 2017 Feb 6.
Results Reference
derived
PubMed Identifier
28013450
Citation
Alarcon Del Agua I, Socas-Macias M, Busetto L, Torres-Garcia A, Barranco-Moreno A, Garcia de Luna PP, Morales-Conde S. Post-implant Analysis of Epidemiologic and Eating Behavior Data Related to Weight Loss Effectiveness in Obese Patients Treated with Gastric Electrical Stimulation. Obes Surg. 2017 Jun;27(6):1573-1580. doi: 10.1007/s11695-016-2495-3.
Results Reference
derived

Learn more about this trial

Abiliti™ Treatment in Obese Subjects

We'll reach out to this number within 24 hrs